{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:19:07Z","timestamp":1795043947772,"version":"4.10.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To compare the prognostic performance of biomarkers soluble fms-like tyrosine kinase-1 (sFlt-1), Placental Growth Factor (PIGF), and sFlt-1\/PIGF ratio as continuous values or as a binary cut-off of 38 for predicting preeclampsia (PE) within 7\u00a0days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Design<\/jats:title>\n                <jats:p>Secondary analysis of a randomised clinical trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Setting<\/jats:title>\n                <jats:p>Oxford University Hospitals, Oxford, United Kingdom (UK).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Population<\/jats:title>\n                <jats:p>Pregnant women between 24<jats:sup>+0<\/jats:sup> to 37<jats:sup>+0<\/jats:sup>\u00a0weeks of gestation with a clinical suspicion of preeclampsia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main outcome<\/jats:title>\n                <jats:p>Onset of preeclampsia within 7\u00a0days of the initial biomarker test.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Logistic regression model for onset of preeclampsia using: (i) sFlt-1 (ii) PIGF, (iii) sFlt-1\/PIGF ratio (continuous), and (iv) sFlt-1\/PIGF ratio as a cut-off above or below 38.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the total 370 women, 42 (11.3%) developed PE within 7\u00a0days of screening. Models with sFlt-1 and sFlt-1\/PIGF ratio (continuous) had greater overall performance than models with PIGF or with sFlt-1\/PIGF ratio as a cut-off at 38 (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>: sFlt-1\u2009=\u200955%, PIGF\u2009=\u200938%, sFlt-1\/PIGF ratio\u2009=\u200957%, sFlt-1\/PIGF ratio as cut-off at 38 model\u2009=\u200946%). The discrimination performance was the highest in sFlt-1 and sFlt-1\/PIGF ratio (continuous) (c-statistic, sFlt-1\u2009=\u20090.94, sFlt-1\/PIGF ratio (continuous)\u2009=\u20090.94) models compared to PIGF or sFlt-1\/PIGF cut-off models (c-statistic, PIGF\u2009=\u20090.87, sFlt-1\/PIGF cut-off\u2009=\u20090.89).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Models using continuous values of sFlt-1 only or sFlt-1\/PIGF ratio had better predictive performance compared to a PIGF only or the model with sFlt-1\/PIGF ratio as a cut-off at 38. Further studies based on a larger sample size are warranted to substantiate this finding.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12884-022-04817-6","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T15:02:45Z","timestamp":1656342165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Meron M.","family":"Kifle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabin","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Vatish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Sofia","family":"Cerdeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric O.","family":"Ohuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"4817_CR1","doi-asserted-by":"publisher","DOI":"10.1081\/PRG-100104165","author":"MA Brown","year":"2001","unstructured":"Brown MA, Lindheimer MD, De Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001. https:\/\/doi.org\/10.1081\/PRG-100104165.","journal-title":"Hypertens Pregnancy"},{"issue":"1","key":"4817_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejogrb.2013.05.005","volume":"170","author":"E Abalos","year":"2013","unstructured":"Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1\u20137. https:\/\/doi.org\/10.1016\/j.ejogrb.2013.05.005.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5 SUPPL.","key":"4817_CR3","first-page":"4","volume":"25","author":"D Hulbert","year":"2008","unstructured":"Hulbert D. Saving mothers\u2019 lives. Emerg Med J. 2008;25(5 SUPPL.):4.","journal-title":"Emerg Med J"},{"key":"4817_CR4","unstructured":"NICE. PIGF-based testing to help diagnose suspected pre-eclampsia (T (Triage riage PIGF test, Elecsys immunoassa immunoassay y sFlt-1 \/ PIGF ratio, DELFIA Xpress PIGF 1\u20132\u20133 test, and BRAHMS sFlt-1 Kryptor \/ BRAHMS PIGF plus Kryptor PE r ratio atio). Nice. 2016;(May):1\u201347.\u00a0ISBN: 978\u20111\u20114731\u20111857\u20117. Available at https:\/\/www.nice.org.uk\/guidance\/dg23."},{"issue":"1","key":"4817_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1414838","volume":"374","author":"H Zeisler","year":"2016","unstructured":"Zeisler H, Llurba E, Chantraine F, et al. Predictive value of the sFlt-1:PIGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374(1):13\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1414838.","journal-title":"N Engl J Med"},{"issue":"1","key":"4817_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12884-018-1992-x","volume":"18","author":"TM MacDonald","year":"2018","unstructured":"MacDonald TM, Tran C, Kaitu\u2019u-Lino TJ, et al. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36weeks\u2019 gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study. BMC Pregnancy Childbirth. 2018;18(1):1\u201312. https:\/\/doi.org\/10.1186\/s12884-018-1992-x.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"1","key":"4817_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2393-14-324","volume":"14","author":"M Hund","year":"2014","unstructured":"Hund M, Allegranza D, Schoedl M, Dilba P, Verhagen-Kamerbeek W, Stepan H. Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): study protocol. BMC Pregnancy Childbirth. 2014;14(1):1\u201310. https:\/\/doi.org\/10.1186\/1471-2393-14-324.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"6","key":"4817_CR8","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1161\/HYPERTENSIONAHA.117.10150","volume":"70","author":"UV Ukah","year":"2017","unstructured":"Ukah UV, Hutcheon JA, Payne B, et al. Placental growth factor as a prognostic tool in women with hypertensive disorders of pregnancy a systematic review. Hypertension. 2017;70(6):1228\u201337. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.10150.","journal-title":"Hypertension"},{"issue":"10183","key":"4817_CR9","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/S0140-6736(18)33212-4","volume":"393","author":"KE Duhig","year":"2019","unstructured":"Duhig KE, Myers J, Seed PT, et al. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet. 2019;393(10183):1807\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(18)33212-4.","journal-title":"Lancet"},{"issue":"2","key":"4817_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1161\/HYPERTENSIONAHA.117.10182","volume":"71","author":"S Agrawal","year":"2018","unstructured":"Agrawal S, Cerdeira AS, Redman C, Vatish M. Meta-analysis and systematic review to assess the role of soluble FMS-like tyrosine kinase-1 and placenta growth factor ratio in prediction of preeclampsia: the SaPPPhirE study. Hypertension. 2018;71(2):306\u201316. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.10182.","journal-title":"Hypertension"},{"issue":"4","key":"4817_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0230955","volume":"15","author":"E Antwi","year":"2020","unstructured":"Antwi E, Amoakoh-Coleman M, Vieira DL, et al. Systematic review of prediction models for gestational hypertension and preeclampsia. PLoS One. 2020;15(4):1\u201324. https:\/\/doi.org\/10.1371\/journal.pone.0230955.","journal-title":"PLoS One"},{"issue":"11","key":"4817_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.preghy.2017.12.002","volume":"2018","author":"YKY Cheng","year":"2017","unstructured":"Cheng YKY, Law LW, Leung TY, Chan OK, Sahota DS. Soluble fms-like tyrosine kinase-1, placental growth factor and their ratio as a predictor for pre-eclampsia in East Asians. Pregnancy Hypertens. 2017;2018(11):61\u20135. https:\/\/doi.org\/10.1016\/j.preghy.2017.12.002.","journal-title":"Pregnancy Hypertens"},{"issue":"1","key":"4817_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-018-3406-1","volume":"18","author":"D Schlembach","year":"2018","unstructured":"Schlembach D, Hund M, Schroer A, Wolf C. Economic assessment of the use of the sFlt-1\/PIGF ratio test to predict preeclampsia in Germany. BMC Health Serv Res. 2018;18(1):1\u201311. https:\/\/doi.org\/10.1186\/s12913-018-3406-1.","journal-title":"BMC Health Serv Res"},{"key":"4817_CR14","doi-asserted-by":"publisher","first-page":"6270187","DOI":"10.1155\/2019\/6270187","volume":"2019","author":"WZ Lou","year":"2019","unstructured":"Lou WZ, Jiang F, Hu J, et al. Maternal serum angiogenic factor sFlt-1 to PIGF ratio in preeclampsia: a useful marker for differential diagnosis and prognosis evaluation in Chinese women. Dis Markers. 2019;2019:6270187. https:\/\/doi.org\/10.1155\/2019\/6270187.","journal-title":"Dis Markers"},{"key":"4817_CR15","doi-asserted-by":"publisher","first-page":"4096847","DOI":"10.1155\/2019\/4096847","volume":"2019","author":"M Hodel","year":"2019","unstructured":"Hodel M, Blank PR, Marty P, Lapaire O. sFlt-1\/PIGF ratio as a predictive marker in women with suspected preeclampsia: an economic evaluation from a Swiss perspective. Dis Markers. 2019;2019:4096847. https:\/\/doi.org\/10.1155\/2019\/4096847.","journal-title":"Dis Markers"},{"issue":"3","key":"4817_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3109\/10641955.2016.1167219","volume":"35","author":"LB Andersen","year":"2016","unstructured":"Andersen LB, Dechend R, J\u00f8rgensen JS, et al. Prediction of preeclampsia with angiogenic biomarkers. Results from the prospective Odense Child Cohort. Hypertens Pregnancy. 2016;35(3):405\u201319. https:\/\/doi.org\/10.3109\/10641955.2016.1167219.","journal-title":"Hypertens Pregnancy"},{"issue":"5","key":"4817_CR17","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1161\/HYPERTENSIONAHA.117.09913","volume":"70","author":"L Saleh","year":"2017","unstructured":"Saleh L, Vergouwe Y, Van Den Meiracker AH, et al. Angiogenic markers predict pregnancy complications and prolongation in preeclampsia: continuous versus cutoff values. Hypertension. 2017;70(5):1025\u201333. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.09913.","journal-title":"Hypertension"},{"issue":"87","key":"4817_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20870","volume":"20","author":"GK Frampton","year":"2016","unstructured":"Frampton GK, Jones J, Rose M, Payne L. Placental growth factor (Alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis. Health Technol Assess (Rockv). 2016;20(87):1\u2013192. https:\/\/doi.org\/10.3310\/hta20870.","journal-title":"Health Technol Assess (Rockv)"},{"issue":"1","key":"4817_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/sim.2331","volume":"25","author":"P Royston","year":"2006","unstructured":"Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25(1):127\u201341. https:\/\/doi.org\/10.1002\/sim.2331.","journal-title":"Stat Med"},{"key":"4817_CR20","doi-asserted-by":"publisher","unstructured":"Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating by Ewout W. Steyerberg. Vol 77. 2009. https:\/\/doi.org\/10.1111\/j.1751-5823.2009.00085_22.x.","DOI":"10.1111\/j.1751-5823.2009.00085_22.x"},{"issue":"4","key":"4817_CR21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/HYPERTENSIONAHA.119.12739","volume":"74","author":"AS Cerdeira","year":"2019","unstructured":"Cerdeira AS, O\u2019Sullivan J, Ohuma EO, et al. Randomized interventional study on prediction of preeclampsia\/eclampsia in women with suspected preeclampsia: INSPIRE. Hypertension. 2019;74(4):983\u201390. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.12739.","journal-title":"Hypertension"},{"issue":"2","key":"4817_CR22","doi-asserted-by":"publisher","first-page":"161.e1","DOI":"10.1016\/j.ajog.2009.09.016","volume":"202","author":"S Verlohren","year":"2010","unstructured":"Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1\/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2010;202(2):161.e1-161.e11. https:\/\/doi.org\/10.1016\/j.ajog.2009.09.016.","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"4817_CR23","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/sim.7992","volume":"38","author":"RD Riley","year":"2019","unstructured":"Riley RD, Snell KIE, Ensor J, et al. Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med. 2019;38(7):1276\u201396. https:\/\/doi.org\/10.1002\/sim.7992.","journal-title":"Stat Med"},{"key":"4817_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jclinepi.2016.03.017","volume":"78","author":"RHH Groenwold","year":"2016","unstructured":"Groenwold RHH, Moons KGM, Pajouheshnia R, et al. Explicit inclusion of treatment in prognostic modeling was recommended in observational and randomized settings. J Clin Epidemiol. 2016;78:90\u2013100. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.03.017.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"4817_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","volume":"21","author":"EW Steyerberg","year":"2010","unstructured":"Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128\u201338. https:\/\/doi.org\/10.1097\/EDE.0b013e3181c30fb2.","journal-title":"Epidemiology"},{"issue":"2","key":"4817_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jclinepi.2014.11.010","volume":"68","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the tripod statement. J Clin Epidemiol. 2015;68(2):112\u201321. https:\/\/doi.org\/10.1016\/j.jclinepi.2014.11.010.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"4817_CR27","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M14-0698","volume":"162","author":"KGM Moons","year":"2015","unstructured":"Moons KGM, Altman DG, Reitsma JB, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1\u201373. https:\/\/doi.org\/10.7326\/M14-0698.","journal-title":"Ann Intern Med"},{"key":"4817_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.l2381","volume":"366","author":"GJ Burton","year":"2019","unstructured":"Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019;366:1\u201315. https:\/\/doi.org\/10.1136\/bmj.l2381.","journal-title":"BMJ"},{"issue":"1","key":"4817_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1471-0528.2012.03496.x","volume":"120","author":"B Payne","year":"2013","unstructured":"Payne B, Hodgson S, Hutcheon JA, et al. Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG An Int J Obstet Gynaecol. 2013;120(1):113\u20138. https:\/\/doi.org\/10.1111\/j.1471-0528.2012.03496.x.","journal-title":"BJOG An Int J Obstet Gynaecol"},{"key":"4817_CR30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1161\/HYPERTENSIONAHA.119.13997","volume":"1","author":"H Perry","year":"2020","unstructured":"Perry H, Binder J, Kalafat E, Jones S, Thilaganathan B, Khalil A. Angiogenic marker prognostic models in pregnant women with hypertension. Hypertension. 2020;1:755\u201361. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13997.","journal-title":"Hypertension"},{"issue":"6","key":"4817_CR31","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/uog.17547","volume":"51","author":"L Saleh","year":"2018","unstructured":"Saleh L, van den Meiracker AH, Geensen R, et al. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia. Ultrasound Obstet Gynecol. 2018;51(6):751\u20137. https:\/\/doi.org\/10.1002\/uog.17547.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"4817_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15338","author":"E Lecarpentier","year":"2020","unstructured":"Lecarpentier E, Zsengell\u00e9r ZK, Salahuddin S, et al. Total versus free placental growth factor levels in the pathogenesis of preeclampsia. Hypertension. 2020. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15338.","journal-title":"Hypertension"},{"issue":"19","key":"4817_CR33","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1161\/CIRCULATIONAHA.113.003215","volume":"128","author":"LC Chappell","year":"2013","unstructured":"Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013;128(19):2121\u201331. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.003215.","journal-title":"Circulation"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-022-04817-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-022-04817-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-022-04817-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T15:07:17Z","timestamp":1656342437000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-022-04817-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4817"],"URL":"https:\/\/doi.org\/10.1186\/s12884-022-04817-6","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"assertion":[{"value":"28 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval of the secondary data analysis of the INSPIRE clinical trial was secured from the Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. The original clinical trial was performed in accordance with the Declaration of Helsinki and is registered at\u2014. Unique identifier: ISRCTN87470468. Informed consent was secured from all study participants by filing a written consent form after being briefed about the study information and consented to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable (NA).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"520"}}